Cadila Healthcare Ahmedabad facility clears USFDA inspection

United States Food and Drug Administration (USFDA) inspected the manufacturing facility of Alidac Pharmaceuticals, the company's wholly-owned subsidiary, at SEZ, Ahmedabad from January 27 to February 4, 2020, Cadila Healthcare said in a BSE filing.

New Delhi: Drug firm Cadila Healthcare on Tuesday said the inspection of its manufacturing facility at Ahmedabad by the US health regulator was completed with no observations.

Also Read: Cadila Healthcare Gujarat Facility Clears USFDA Inspection

United States Food and Drug Administration (USFDA) inspected the manufacturing facility of Alidac Pharmaceuticals, the company's wholly-owned subsidiary, at SEZ, Ahmedabad from January 27 to February 4, 2020, Cadila Healthcare said in a BSE filing.

"At the end of the inspection, no observation (483) is issued. The site manufactures oncology injectables for the regulated markets," it added.

Also Read: Cadila Healthcare To Merge With 4 Subsidiaries To Cut Costs, Overheads